PDCD1 and urothelial carcinoma: In a subsequent study, they assessed the relationship between antibiotic use and the gut microbiome in patients with NSCLC (n = 140), RCC (n = 67), or urothelial carcinoma (n = 42) who received PD-1/PD-L1 after one or several previous therapies [26].